Collection 6 (Sep 2025 – Aug 2026) Articles

Articles
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis
Nicholls SJ, Nelson AJ, Ray KK, et al.
Journal:
J Am Coll Cardiol

First published: October 7, 2025 DOI: 10.1016/j.jacc.2025.07.056
View
- Share
Articles
South Asian Representation in Cardiovascular Disease Randomized Controlled Trials: A Systematic Review
Uppal N, Patel AP, Bhatt DL, et al.
Journal:
JACC Asia

First published: October 5, 2025 DOI: 10.1016/j.jacasi.2025.06.017
View
- Share
Articles
Great debate: fire-and-forget beats personalized lipid-lowering treatment
Tokgozoglu, L
Journal:
Eur Heart J

First published: October 3, 2025 DOI: 10.1093/eurheartj/ehaf567
View
- Share
Articles
Factors Associated with Elevated High-Sensitivity C-Reactive Protein Levels in Individuals with Atherosclerotic Cardiovascular Disease in the US and the UK
Ray KK, Reuter SB, Dalbeler A, et al.
Journal:
Eur J Prev Cardiol

First published: October 1, 2025 DOI: 10.1093/eurjpc/zwaf609
View
- Share
Articles
Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid: Clinical Insights From CLEAR Outcomes
Ray KK, Nicholls SJ, Lincoff AM, et al.
Journal:
JACC Adv

First published: September 26, 2025 DOI: 10.1016/j.jacadv.2025.102207
View
- Share
Articles
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy
Reijnders E, Bossuyt P, Jukema JW, et al.
Journal:
Arterioscler Thromb Vasc Biol

First published: September 25, 2025 DOI: 10.1161/ATVBAHA.124.322336
View
- Share
Articles
Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia
Landmesser U, Laufs U, Schatz U, et al.
Journal:
Am Heart J

First published: May 26, 2025 DOI: 10.1016/j.ahj.2025.05.014
View
- Share

Collection 6 (Sep 2025 – Aug 2026) Articles

Articles

Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis

Nicholls SJ, Nelson AJ, Ray KK, et al.

Articles

South Asian Representation in Cardiovascular Disease Randomized Controlled Trials: A Systematic Review

Uppal N, Patel AP, Bhatt DL, et al.

Articles

Great debate: fire-and-forget beats personalized lipid-lowering treatment

Tokgozoglu, L

Articles

Factors Associated with Elevated High-Sensitivity C-Reactive Protein Levels in Individuals with Atherosclerotic Cardiovascular Disease in the US and the UK

Ray KK, Reuter SB, Dalbeler A, et al.

Articles

Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid: Clinical Insights From CLEAR Outcomes

Ray KK, Nicholls SJ, Lincoff AM, et al.

Articles

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

Reijnders E, Bossuyt P, Jukema JW, et al.

Articles

Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia

Landmesser U, Laufs U, Schatz U, et al.

Articles

Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis

Nicholls SJ, Nelson AJ, Ray KK, et al.

Share

Articles

South Asian Representation in Cardiovascular Disease Randomized Controlled Trials: A Systematic Review

Uppal N, Patel AP, Bhatt DL, et al.

Share

Articles

Great debate: fire-and-forget beats personalized lipid-lowering treatment

Tokgozoglu, L

Share

Articles

Factors Associated with Elevated High-Sensitivity C-Reactive Protein Levels in Individuals with Atherosclerotic Cardiovascular Disease in the US and the UK

Ray KK, Reuter SB, Dalbeler A, et al.

Share

Articles

Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid: Clinical Insights From CLEAR Outcomes

Ray KK, Nicholls SJ, Lincoff AM, et al.

Share

Articles

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

Reijnders E, Bossuyt P, Jukema JW, et al.

Share

Articles

Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia

Landmesser U, Laufs U, Schatz U, et al.

Share